CDMO

Samsung Biologics to purchase land for its second Bio Campus

Retrieved on: 
Monday, July 18, 2022
Open innovation, IFEZ, CEO, Patient, United States Air Force Plant 4, Samsung Biologics, Incheon Free Economic Zone, KRX, CDMO, KRW, Samsung, Mobile phone

The additionally acquired land is located within Songdo Industrial Cluster, covering an area of 357,366 square meters which is 30% larger than the company's current campus.

Key Points: 
  • The additionally acquired land is located within Songdo Industrial Cluster, covering an area of 357,366 square meters which is 30% larger than the company's current campus.
  • Bio Campus II is designed to support Samsung Biologics' further expansion of large-scale manufacturing capacity as well as host a multi-modal plant and an open innovation facility.
  • The land was awarded to Samsung Biologics in accordance with the IFEZ's strategy to strengthen the region's global competitiveness in the biopharma sector while fostering partnerships with small and mid-sized venture companies.
  • "Samsung Biologics' achievements over the past decade are remarkable and highly impressive," said Jeong Bok Yoo, Mayor of Incheon Metropolitan City.

Calibre One Adds New Partner to its Global Recruitment Firm

Retrieved on: 
Monday, July 18, 2022
Leadership, STEM, Chief executive officer, Acquisition, SALT, Virginia University, Knowledge, Program, Student, Technology, MBA, Salt Lake, Digital technology, Marketing, West Virginia University, Organization, Risk, CDMO, USTA, Management, Intermountain West, Western Governors University

SALT LAKE CITY, July 18, 2022 /PRNewswire-PRWeb/ -- Calibre One, a leading global executive search boutique specializing in building leadership teams for innovators, entrepreneurs and companies undergoing technology or digital transformation, announces the appointment of Betsy Patterson as partner. Based in Salt Lake City, Utah, Patterson will leverage her 30 years' experience within the life sciences and healthcare industries to expand Calibre One's position in this increasingly critical market throughout the United States.

Key Points: 
  • Calibre One, a leading global executive search boutique specializing in building leadership teams for innovators, entrepreneurs and companies undergoing technology or digital transformation, announces the appointment of Betsy Patterson as partner.
  • SALT LAKE CITY, July 18, 2022 /PRNewswire-PRWeb/ -- Calibre One, a leading global executive search boutique specializing in building leadership teams for innovators, entrepreneurs and companies undergoing technology or digital transformation, announces the appointment of Betsy Patterson as partner.
  • "This advisory component of my experience brings a unique perspective to the entire recruitment process, and I'm excited to put this knowledge to work at Calibre One."
  • The Calibre One process includes a proprietary measure that aligns client and candidate diversity and inclusion objectives, every search, every time.

Global Oral Solid Dosage Contract Manufacturing Market to 2027 - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, July 15, 2022
Health, Pharmaceutical, Degenerative disease, Patient, Investment, CAGR, Pfizer, CMOS, Tablet, Hydroxychloroquine, COVID-19, Azithromycin, Industry, Gilead Sciences, Contract, Growth, CDMO, OSD, R, Intention, Fine chemical, Pharmaceutical industry

Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly.

Key Points: 
  • Oral solids are the most widely accepted dosage forms in the pharmaceutical sector as they are cost-effective, simple to manufacture, and patient-friendly.
  • Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing drive the market growth.
  • The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and a high level of adaptability.
  • Chapter 3 Oral Solid Dosage Contract Manufacturing Market: Variables, Trends, & Scope
    3.2.2.2 Less availability of experienced technical staff, as well as physical capability and capacity of the equipment.

Altasciences Continues Manufacturing Expansion in Philadelphia With Client‑Dedicated Building Project

Retrieved on: 
Friday, July 15, 2022
Other Manufacturing, Research, Consulting, Clinical Trials, Professional Services, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Pharmacology, Therapy, II, CRO, General manager, Medical writing, Drug development, Immunoglobulin E, Biotechnology, CDMO, Data management, Workforce, Biostatistics, Fine chemical, Pharmaceutical industry

Altasciences formulation, manufacturing, and analytical services facilities in Philadelphia, PA, are undergoing further expansion.

Key Points: 
  • Altasciences formulation, manufacturing, and analytical services facilities in Philadelphia, PA, are undergoing further expansion.
  • Altasciences will manage all aspects of this project, including warehousing, release management, manufacturing, quality assurance, and finished product release.
  • The new building will have additional client dedicated capacity that can be used for Phase I through to commercial manufacturing services.
  • The training Altasciences provides their CDMO workforce is second to none, as each team member is well-equipped to optimize and complete our manufacturing projects.

Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo

Retrieved on: 
Thursday, July 14, 2022
Compliance, Biotechnology, IV, Society, BCS, Pharmacokinetics, Program, Genetics, ASRM, Congress, III, Peptide, Gonadotropin-releasing hormone, American Society for Reproductive Medicine, Anaheim Convention Center, Practice management, Nasdaq, Woman, CDMO, Area studies, Reproductive medicine, Research, Gene, Infertility, Leuprorelin, Pharmaceutical industry

"We are looking forward to presenting our findings at ASRM 2022 highlighting the pharmacokinetic properties of Enteris' oral tablet formulation of leuprolide and its ability to achieve drug levels exceeding those of approved injectable leuprolide products," said Enteris Chief Medical Officer Dr. Gary Shangold.

Key Points: 
  • "We are looking forward to presenting our findings at ASRM 2022 highlighting the pharmacokinetic properties of Enteris' oral tablet formulation of leuprolide and its ability to achieve drug levels exceeding those of approved injectable leuprolide products," said Enteris Chief Medical Officer Dr. Gary Shangold.
  • Women are disproportionately impacted by such diseases, and we believe access to next-generation treatments, such as oral leuprolide, are increasingly needed."
  • The title of the abstract follows:
    The in-person presentation will at the ASRM Scientific Congress & Expo at the Anaheim Convention Center on Oct26, 2022, 11:05 AM Pacific Time.
  • For more information on Enteris BioPharma and its proprietary oral drug delivery technologies, please visit http://www.EnterisBioPharma.com .

GenScript ProBio and DAAN Bio Therapeutics, Sign a Strategic Cooperation MOU for the Discovery and Development of Novel Drugs

Retrieved on: 
Thursday, July 14, 2022
NK, Tissue, Antibody, CGT, CMO, Multimedia, DAAN, IND, Therapy, GenScript Biotech, Patient, Drug discovery, CEO, Research, GMP, Koch Institute for Integrative Cancer Research, CDMO, Cancer, Drug development, Partnership, Pharmaceutical industry, Fine chemical, Vaccine

GenScript ProBio and DAAN have agreed to strengthen their cooperation in the cell and gene therapy (CGT) and biologics field through this MOU.

Key Points: 
  • GenScript ProBio and DAAN have agreed to strengthen their cooperation in the cell and gene therapy (CGT) and biologics field through this MOU.
  • Through this agreement, both companies will strategically cooperate in the overall development process, such as discovery, manufacturing, and clinical trials of antibody and cell treatments, and related research and service projects.
  • Through this strategic partnership, both GenScript ProBio and DAAN Bio Therapeutics will continue their cooperation more closely with each other to develop subsequent pipelines of DAANBio Therapeutics, such as antibody drug and cell therapy.
  • Developer of integrated immune-oncology drug research platform intended to find various treatment strategies and develop novel drugs for lung cancer therapy.

Enveric Biosciences Advances Drug Development for Mental Health Indications and Intellectual Property Portfolio

Retrieved on: 
Wednesday, July 13, 2022
Mental Health, Research, Clinical Trials, Biotechnology, Alternative Medicine, Health, Pharmaceutical, Other Science, Science, Knowledge, Pharmacology, SEC, Clinical trial, Anxiety, GSK, Security (finance), Biotechnology, U.S. Securities and Exchange Commission, NASDAQ, Program, Leadership, Contract, WCG, IND, Intention, World Intellectual Property Organization, Patient, Drug discovery, Psilocybin, COVID-19, PTSD, Depression, Phrase, IP, Toxicology, Freedom, PCT, Intellectual property, Sanofi, Research and development, File, Forward-looking statement, CDMO, Toxicity, Cros, Translational research, Board, CNS, Innovation, Nature, Drug development, Doctor of Philosophy, Coronavirus, Pharmaceutical industry, MD, Research, Enver Pasha

Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property (IP) advances achieved during the first half of 2022.

Key Points: 
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today revealed drug discovery and development progress targeting mental health indications and intellectual property (IP) advances achieved during the first half of 2022.
  • Enverics Clinical Team is led by a past Board-certified psychiatrist and clinical trialist Chief Medical Officer, Dr. Bob Dagher, MD.
  • The first half of the year has indeed been busy and productive for the dedicated team here at Enveric.
  • Enveric Biosciences, Inc. (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines.

Global Pharmaceutical Contract Manufacturing & Research Services Market Report, 2022-2027 - Featuring Profiles of Thermo Fisher Scientific, AbbVie, Baxter BioPharma, Dalton Pharma Services, and Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 13, 2022
Pharmaceutical, Health, Other Manufacturing, Manufacturing, Economy, Pharmaceutical Research and Manufacturers of America, Clinical trial, PPD, Inc., CTI, BioNTech, Program, OECD, Vaccine, Lists of countries and territories, ICON, AbbVie, CRO, Pharmacy, Review, GDP, Thermo Fisher Scientific, COVID-19, Recipharm, Organization, CDMO, Consultant, CAGR, PPD, Research, Gross domestic product, Plasma protein binding, Drug development, Partnership, Pharmaceutical industry, Fine chemical, Pfizer, Moderna, Growth

The Pharmaceutical Contract Manufacturing and Research Services Market is expected to register a CAGR of nearly 7% over the forecast period, 2022-2027.

Key Points: 
  • The Pharmaceutical Contract Manufacturing and Research Services Market is expected to register a CAGR of nearly 7% over the forecast period, 2022-2027.
  • The COVID-19 pandemic has significantly impacted the pharmaceutical contract manufacturing and research manufacturing research services market.
  • Growing demand to develop pharmaceutical drugs is driving the demand for pharmaceutical contract manufacturing and research services market.
  • The pharmaceutical contract manufacturing and research services market is competitive with the presence of several global and international market players.

GenScript ProBio Signs MOU to Form Strategic Partnership with ACT Therapeutics to Development of New CAR-T Cell Therapies

Retrieved on: 
Wednesday, July 13, 2022
ACT, Technology, Safety, CGT, Multimedia, IND, Therapy, CAR, GenScript Biotech, Drug discovery, CEO, GMP, MOU, CDMO, Lymphatic system, Drug development, Partnership, Pharmaceutical industry, Medical device, Vaccine

GenScript ProBio and ACT Therapeutics have agreed to strengthen their cooperation in the cell therapy field through this MOU.

Key Points: 
  • GenScript ProBio and ACT Therapeutics have agreed to strengthen their cooperation in the cell therapy field through this MOU.
  • GenScript ProBio and ACT Therapeutics are in the process of signing a contract for plasmid and virus vector development and production for the first pipeline of ACT Therapeutics' Advanced CAR-T Platform (ACT platform), which will also be commissioned to produce raw materials for ACT Therapeutics' subsequent pipeline.
  • With this agreement, GenScript ProBio has become a global partner that can support ACT platforms for ACT therapeutics.
  • Seogkyoung-Kong, CEO of ACT Therapeutics, said, "We have completed preparations for the ACT platform to emerge globally through a strategic partnership with GenScript ProBio.

Outlook on the Pharmaceutical Analytical Testing Outsourcing Global Market to 2027 - Increasing focus on Regulation, Safety and Quality is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 12, 2022
Research, Genetics, Clinical Trials, Professional Services, Biotechnology, Data Analytics, Pharmaceutical, Health, Science, Other Science, Minister of Finance (Malaysia), Technology, PPD, Inc., NGS, LLC, Acquisition, Biopharmaceutical, LabCorp, Genomics, Pharmacy, Pace, Drug discovery, DDE, NIH, CDMO, Research, Adoption, Growth, National Institute, Cancer, Foundation for the National Institutes of Health, USD, Liquid biopsy, Fine chemical, Pharmaceutical industry, Eurofins Scientific

In addition, rising mergers and acquisitions among the key market players are further expected to drive the growth of this segment studied.

Key Points: 
  • In addition, rising mergers and acquisitions among the key market players are further expected to drive the growth of this segment studied.
  • North America holds a major share in the pharmaceutical analytical testing outsourcing market during the forecast period.
  • Such developments in the United States will lead to increased adoption of pharmaceutical analytical testing outsourcing services in this region, thereby, driving the market growth.
  • Therefore, the rise in research funding for such activities will lead to increased adoption of pharmaceutical analytical testing outsourcing services, driving regional market growth.